Clinical guideline for 9-valent HPV vaccine: Korean society of gynecologic oncology guideline

Kyung Jin Min, Sang Hoon Kwon, Kidong Kim, Sunghoon Kim, Hyun Jung Kim, Seok Ju Seong, Yong Jung Song, Keun Ho Lee, Shin Wha Lee, Jeong Won Lee, Suk Joon Chang, Woong Ju, Young Tak Kim, Jae Kwan Lee

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.

Original languageEnglish
Article numbere31
JournalJournal of Gynecologic Oncology
Volume30
Issue number2
DOIs
StatePublished - Mar 2019

Bibliographical note

Publisher Copyright:
© 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.

Keywords

  • Female
  • Male
  • Papillomavirus vaccines
  • Practice guidelines

Fingerprint

Dive into the research topics of 'Clinical guideline for 9-valent HPV vaccine: Korean society of gynecologic oncology guideline'. Together they form a unique fingerprint.

Cite this